Cancer Drugs Fund reveals drugs proposed for de-listing

clock

Key points

NHS announces changes as projections show rise to £410m in costs without de-listings

The NHS has proposed removing some drugs from the list of those funded by the Cancer Drugs Fund (CDF).

In cases where a drug is proposed for removal, but does offer "enough clinical benefit", companies can reduce their asking price to avoid being removed.

The NHS has warned that it does not expect the CDF to be on budget this year, but should be within budget during 2016/17.

Patients currently receiving treatments available from the CDF will continue to do so even if they are removed from the list.

The NHS has increased the CDF's budget from £200m in 2013/14 to £340m from April 2015, an increase of 70% since August 2014.

Without further changes to the fund spending on the CDF would rise to around £410m.

Drugs due to be removed include Albumin Bound Paclitaxel, used to treat advanced adenocarcinoma of the pancreas and Bendamustine, used in the treatment of Chronic Lymphocytic Leukaemia.

Drugs which will remain funded by the CDF include Eribulin, used in the treatment of breast cancer, and Pegylated Liposomal Doxorubicin, used in the treatment of sarcomas.

A complete list of those drugs within the Fund, and those scheduled for removal, can be found here.

Announcing the changes, Professor Peter Clark, chair of the Cancer Drugs Fund, said: "There is no escaping the fact that we face a difficult set of choices, but it is our duty to ensure we get maximum value from every penny available on behalf of patients.

"We must ensure we invest in those treatments that offer the most benefit, based on rigorous evidence-based clinical analysis and an assessment of the cost of those treatments."

Further reading:

APRIL UK upgrades cancer benefits on inSpire plan

Head and neck cancer survival rate variations revealed

'Wrong to assume' older patients more likely to refuse cancer treatment - Macmillan

 

Key points

NHS announces changes as projections show rise to £410m in costs without de-listings

More on Regulation

FCA 'disappointed' over product governance and fair value compliance failures

FCA 'disappointed' over product governance and fair value compliance failures

Regulator calls out inadequate response to Policy Statement 21/5

Hemma Visavadia
clock 12 August 2022 • 3 min read
Consumer Duty: When is an extension not an extension?

Consumer Duty: When is an extension not an extension?

“Any provider worth its salt should be doing a lot of these things already”

John Brazier
clock 03 August 2022 • 3 min read
FCA tightens AR rules to cut mis-selling risk

FCA tightens AR rules to cut mis-selling risk

Greater onus on principals

Jenna Brown
clock 03 August 2022 • 2 min read

Highlights

FCA gives three-month Consumer Duty extension for advisers

FCA gives three-month Consumer Duty extension for advisers

Deadline of 31 July 2023

Hemma Visavadia
clock 27 July 2022 • 5 min read
Meet the firm turning professional athletes into protection advisers

Meet the firm turning professional athletes into protection advisers

"You're only ever as good as your last game, but your next game could be your last"

Hemma Visavadia
clock 25 July 2022 • 5 min read
The COVER Review July 2022: Protection & Financial Education, IPAW 2022 and Reviewing 2022 So Far

The COVER Review July 2022: Protection & Financial Education, IPAW 2022 and Reviewing 2022 So Far

Now available for members to watch

John Brazier
clock 20 July 2022 • 1 min read